Experimental infection and protection against ... - TI Pharma

Efficacy of pre-erythrocytic and blood-stage malaria vaccines can be assessed in small
sporozoite challenge trials in human volunteers
References
1. Sauerwein RW, Roestenberg M, Moorthy VS. Experimental human challenge
infections can accelerate clinical malaria vaccine development. Nat Rev
Immunol 2011; 11:57-64.
2. Hermsen CC, Telgt DS, Linders EH, et al. Detection of Plasmodium falciparum
malaria parasites in vivo by real-time quantitative PCR. Mol Biochem Parasitol
2001; 118:247-251.
3. Olotu A, Lusingu J, Leach A, et al. Efficacy of RTS,S/AS01E malaria vaccine and
exploratory analysis on anti-circumsporozoite antibody titres and protection in
children aged 5-17 months in Kenya and Tanzania: a randomised controlled
trial. Lancet Infect Dis 2011; 11:102-109.
4. Cummings JF, Spring MD, Schwenk RJ, et al. Recombinant Liver Stage Antigen-1
(LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and
induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental
Plasmodium falciparum infection. Vaccine 2010; 28:5135-5144.
5. Genton B, D'Acremont V, Lurati-Ruiz F, et al. Randomized double-blind
controlled Phase I/IIa trial to assess the efficacy of malaria vaccine PfCS102 to
protect against challenge with P. falciparum. Vaccine 2010; 28:6573-6580.
6. Hermsen CC, de Vlas SJ, van Gemert GJ, Telgt DS, Verhage DF, Sauerwein RW.
Testing vaccines in human experimental malaria: statistical analysis of
parasitemia measured by a quantitative real-time polymerase chain reaction.
Am J Trop Med Hyg 2004; 71:196-201.
7. Spring MD, Cummings JF, Ockenhouse CF, et al. Phase 1/2a study of the malaria
vaccine candidate apical membrane antigen-1 (AMA-1) administered in
adjuvant system AS01B or AS02A. PLoS One 2009; 4:e5254.
8. Heppner DG, Jr., Kester KE, Ockenhouse CF, et al. Towards an RTS,S-based,
multi-stage, multi-antigen vaccine against falciparum malaria: progress at the
Walter Reed Army Institute of Research. Vaccine 2005; 23:2243-2250.
9. White MT, Griffin JT, Drakeley CJ, Ghani AC. Heterogeneity in malaria exposure
and vaccine response: implications for the interpretation of vaccine efficacy
trials. Malar J 2010; 9:82.
10. Ponnudurai T, Lensen AH, van Gemert GJ, Bensink MP, Bolmer M, Meuwissen
JH. Infectivity of cultured Plasmodium falciparum gametocytes to mosquitoes.
Parasitology 1989; 98 Pt 2:165-173.
11. Pombo DJ, Lawrence G, Hirunpetcharat C, et al. Immunity to malaria after
administration of ultra-low doses of red cells infected with Plasmodium
falciparum. Lancet 2002; 360:610-617.
12. World Malaria Report. Available at: http://www.who.int/malaria. Accessed 28
July 2011.
13. Malaria Vaccine Roadmap. Available at:
http://www.malariavaccine.org/malvac-roadmap.php. Accessed 28 July 2011.
14. Target Product Profile RTS`S. Available at: http://www.who.int/vaccinesdocuments/DocsPDF04/www773.pdf.
Accessed 28 July 2011.
127